Case Report
Copyright ©2009 The WJG Press and Baishideng.
World J Gastroenterol. Apr 14, 2009; 15(14): 1779-1781
Published online Apr 14, 2009. doi: 10.3748/wjg.15.1779
Figure 2
Figure 2 Clinical course of this patient. First, 400 mg/d of oral UFT-E was started. We then placed an intra-arterial catheter that delivered medication into the aorta just before the bronchial arteries, and docetaxel (80 mg/body initially, followed by 40 mg/body) and CDDP (50 mg/body initially, followed by 20 mg/body) were administered every 2 wk via a subcutaneous injection port. Levels of PIVKA-II, a tumor marker, decreased rapidly 1 mo after starting chemotherapy; levels continued to fall to normal and were maintained.